ANAPTYSBIO, INC. Tax Withholding Paid on Stock Awards
ANAPTYSBIO, INC. (ANAB) reported Tax Withholding Paid on Stock Awards of $0 for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-09-21
- ANAPTYSBIO, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $0.00.
- ANAPTYSBIO, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- ANAPTYSBIO, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $0.00.
- ANAPTYSBIO, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $0.00.
- ANAPTYSBIO, INC. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $1.45M, a 80.66% decline from fiscal 2024.
- ANAPTYSBIO, INC. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $7.50M.
- ANAPTYSBIO, INC. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $0.00.
- ANAPTYSBIO, INC. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $0.00.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $0.00 10-KT · filed 2026-09-21 | $0.00 derived: sum of 3 quarters · filed 2026-09-21 | $0.00 derived: sum of 4 quarters · filed 2026-09-21 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-09-21 | $0.00 derived: sum of 3 quarters · filed 2026-09-21 | $0.00 derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-12-31 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $0.00 derived: sum of 2 quarters · filed 2026-09-21 | $0.00 derived: sum of 3 quarters · filed 2026-09-21 | $1.45M 10-KT · filed 2026-09-21 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-KT 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2026-09-21 | $1.45M 10-Q · filed 2025-11-04 | $1.45M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-06-30 | $0.00 derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $1.45M 10-KT · filed 2026-09-21 | $1.45M derived: sum of 3 quarters · filed 2026-09-21 | $1.45M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-03-31 | $1.45M 10-Q · filed 2026-05-12 | $1.45M derived: sum of 2 quarters · filed 2026-09-21 | $1.45M derived: sum of 3 quarters · filed 2026-09-21 | $1.45M derived: sum of 4 quarters · filed 2026-09-21 |
| 2024-12-31 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $0.00 derived: sum of 2 quarters · filed 2026-09-21 | $0.00 derived: sum of 3 quarters · filed 2026-09-21 | $7.50M 10-KT · filed 2026-09-21 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $7.50M 10-Q · filed 2025-11-04 | $7.50M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $7.50M 10-Q · filed 2025-08-06 | $7.50M derived: sum of 3 quarters · filed 2026-03-03 | $7.50M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $7.50M 10-Q · filed 2025-05-05 | $7.50M derived: sum of 2 quarters · filed 2026-03-03 | $7.50M derived: sum of 3 quarters · filed 2026-03-03 | $7.50M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 derived: sum of 3 quarters · filed 2026-03-03 | $0.00 10-K · filed 2026-03-03 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $0.00 derived: sum of 2 quarters · filed 2024-11-05 | $0.00 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $0.00 10-Q · filed 2024-08-05 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |